FDA Approves Bevacizumab Biosimilar for Six Cancer Types

The FDA has approved bevacizumab-abcd for use in nonsquamous non–small cell lung cancer, recurrent glioblastoma, metastatic colorectal cancer, persistent, recurrent, or metastatic cervical cancer, metastatic renal cell carcinoma, and epithelial ovarian, fallopian tube, and primary peritoneal cancer. The FDA has granted approval to bevacizumab-adcd (Vegzelma), a biosimilar to bevacizumab...
Picture for FDA Approves Bevacizumab Biosimilar for Six Cancer Types

Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment

Millie Das, MD: I presented an e-poster looking at the cost-effectiveness of atezolizumab for adjuvant treatment in the FDA-labeled patient population. These are stage II and IIIA patients who are PD-L1–positive who have undergone resection. For many years in early stage non–small cell lung cancer, the standard adjuvant treatment option has been chemotherapy. Now we have our first immunotherapy indication in this adjuvant non–small cell lung cancer space. It’s important to see whether the additional cost of immunotherapy is worth it, especially with the knowledge that immunotherapy can be expensive compared with many of our chemotherapy drugs. We did this cost-effective analysis to try to answer this question.
Picture for Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment

FDA approves Vegzelma, biosimilar to Avastin, for treatment of six cancer types

The FDA approved bevacizumab-adcd for treatment of six cancer types, according to a press release from the biosimilar’s manufacturer. Bevacizumab-adcd (Vegzelma, Celltrion USA), a biosimilar to bevacizumab (Avastin, Genentech), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and prohibits it from binding to VEGFR-1 and VEGFR-2 on the surface of endothelial cells.
Picture for FDA approves Vegzelma, biosimilar to Avastin, for treatment of six cancer types

BMP2 promotes lung adenocarcinoma metastasis through BMP receptor 2-mediated SMAD1/5 activation

Bone morphogenetic protein 2 (BMP2) is highly overexpressed in human non-small cell lung cancer (NSCLC) and correlates with tumor stage and metastatic burden. Although several lines of evidence suggest that BMP2 promotes cell migration and invasiveness in vitro, the in vivo role of BMP2 in the metastasis of lung adenocarcinoma cells remains less well understood. Here, we revealed that BMP2 is highly overexpressed in lung adenocarcinoma patients with lymph node metastasis compared with patients without lymph node metastasis. Using an in vivo orthotopic mouse model, we clearly demonstrated that BMP2 promotes lung adenocarcinoma metastasis. The depletion of BMP2 or its receptor BMPR2 significantly reduced cell migration and invasiveness. We further identified that BMP2/BMPR2-mediated cell migration involves the activation of the SMAD1/5/8 signaling pathway, independent of the KRAS signaling pathway. Significantly, the depletion of SMAD1/5/8 or the inhibition of SMAD1/5/8 by LDN193189 inhibitor significantly reduced cell migration. These findings show that BMP2 promotes NSCLC metastasis, indicating that targeting the BMP2 signaling pathway may represent a potential therapeutic strategy for treating patients with metastatic NSCLC.

Many Patients With Advanced NSCLC Do Not Survive Beyond First-Line Therapy

Many patients with advanced non-small cell lung cancer (NSCLC) do not survive long enough to receive second-line therapy, according to a real-world study published in Cancer Treatment and Research Communications. Of the nearly 500 patients evaluated in this study, 60% received first-line therapy only, and 42% of those patients did...

Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer

More and more, people with lung cancer are receiving treatments that zero in on specific genetic changes in their tumors (targeted therapies). Now patients with non-small cell lung cancer (NSCLC) have another targeted therapy option. On August 11, the Food and Drug Administration (FDA) gave accelerated approval to trastuzumab deruxtecan...

Thermo Fisher's Oncomine Dx Test Is First FDA Approved NGS-Based Companion Diagnostic To Detect Thyroid Cancers

The FDA approved Thermo Fisher Scientific Inc's TMO Oncomine Dx Target Test as a companion diagnostic (CDx) to select patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and thyroid cancer who may be eligible for Eli Lilly And Co's LLY Retevmo (selpercatinib) treatment. This marks...

Dr Joshua Sabari on Burden, Treatment Options for Patients With KRAS-Mutated NSCLC

Joshua Sabari, MD, a thoracic medical oncologist, Perlmutter Cancer Center, NYU Langone Health, discusses actionable mutations in advanced non–small cell lung cancer (NSCLC). KRAS mutations as a whole make up about 30% of cases of non–small cell lung cancer, most commonly in older patients, smokers, or those who have...

Incidental sinoatrial node irradiation may increase AF risk in lung cancer

MedwireNews: Incidental irradiation of the sinoatrial node (SAN) during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation (AF) and death, research suggests. Seok-Min Kang (Yonsei University College of Medicine, Seoul, Republic of Korea) and colleagues say their findings account for “the need to minimize radiation...
MedPage Today

Targeted Agent Bests Chemo in Second-Line for KRAS-Mutant NSCLC

Targeted therapy with sotorasib (Lumakras) in previously treated non-small cell lung cancer (NSCLC) patients harboring KRAS-G12C mutations reduced the risk of disease progression or death by 34% compared with standard second-line chemotherapy, according to a phase III trial presented at the annual congress of the European Society for Medical Oncology (ESMO).